Enlivex Net Tangible Assets vs Short Term Investments Analysis

ENLV Stock

USD 1.14 0.07 6.54%

Enlivex Therapeutics financial indicator trend analysis is much more than just examining Enlivex Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Enlivex Therapeutics is a good investment. Please check the relationship between Enlivex Therapeutics Net Tangible Assets and its Short Term Investments accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.

Net Tangible Assets vs Short Term Investments

Net Tangible Assets vs Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Enlivex Therapeutics Net Tangible Assets account and Short Term Investments. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Enlivex Therapeutics' Net Tangible Assets and Short Term Investments is 0.58. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Short Term Investments in the same time period over historical financial statements of Enlivex Therapeutics, assuming nothing else is changed. The correlation between historical values of Enlivex Therapeutics' Net Tangible Assets and Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Enlivex Therapeutics are associated (or correlated) with its Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Investments has no effect on the direction of Net Tangible Assets i.e., Enlivex Therapeutics' Net Tangible Assets and Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.58

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Short Term Investments

Short Term Investments is an item under the current assets section of Enlivex Therapeutics balance sheet. It contains any investments Enlivex Therapeutics undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Enlivex Therapeutics can easily liquidate in the marketplace.

Most indicators from Enlivex Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Enlivex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.Selling General Administrative is likely to climb to about 8.1 M in 2024, despite the fact that Tax Provision is likely to grow to (3.4 K).

	2021	2022	2023	2024 (projected)
Cost Of Revenue	546K	777K	835K	793.3K
Research Development	12.9M	18.7M	19.2M	20.2M

Cost Of Revenue Research Development

Enlivex Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Accounts Payable	Cash	Other Assets	Short Term Investments	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Treasury Stock	Long Term Debt	Good Will	Preferred Stock Total Equity	Other Liab	Net Debt	Retained Earnings	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Current Assets
Total Assets		0.48	0.75	1.0	0.73	0.5	0.5	0.46	-0.33	0.81	0.6	0.47	0.37	0.03	0.56	0.57	-0.56	0.8	-0.32	-0.23	0.63	0.12	0.41	0.47	0.42	0.62
Other Current Liab	0.48		0.88	0.43	0.24	0.19	0.63	0.12	-0.61	0.81	0.05	0.85	0.7	0.52	-0.08	0.13	0.08	0.66	-0.14	-0.71	0.51	0.54	0.88	0.84	0.71	0.51
Total Current Liabilities	0.75	0.88		0.71	0.56	0.46	0.72	0.15	-0.55	0.91	0.34	0.7	0.61	0.34	0.26	0.32	-0.26	0.74	-0.33	-0.53	0.54	0.49	0.7	0.69	0.59	0.55
Total Stockholder Equity	1.0	0.43	0.71		0.75	0.48	0.47	0.47	-0.3	0.77	0.63	0.41	0.33	0.01	0.6	0.6	-0.6	0.78	-0.29	-0.18	0.59	0.08	0.36	0.41	0.37	0.58
Accounts Payable	0.73	0.24	0.56	0.75		0.49	0.55	-0.01	-0.02	0.46	0.7	0.05	0.32	0.01	0.65	0.69	-0.65	0.53	-0.28	-0.05	0.09	-0.09	0.02	0.06	0.13	0.19
Cash	0.5	0.19	0.46	0.48	0.49		0.5	-0.18	-0.27	0.59	0.11	0.29	0.31	-0.26	0.17	0.07	-0.17	0.42	-0.96	-0.2	0.41	0.08	0.22	0.3	0.33	0.42
Other Assets	0.5	0.63	0.72	0.47	0.55	0.5		-0.19	-0.29	0.65	0.35	0.56	0.89	0.59	0.21	0.38	-0.21	0.8	-0.35	-0.65	0.2	-0.11	0.53	0.58	0.55	0.2
Short Term Investments	0.46	0.12	0.15	0.47	-0.01	-0.18	-0.19		0.16	0.34	-0.03	0.35	-0.05	0.08	-0.04	-0.07	0.04	0.33	0.17	-0.02	0.66	0.12	0.32	0.34	0.27	0.64
Other Current Assets	-0.33	-0.61	-0.55	-0.3	-0.02	-0.27	-0.29	0.16		-0.55	-0.03	-0.54	-0.33	-0.13	0.01	-0.06	-0.01	-0.38	0.25	0.55	-0.43	-0.43	-0.55	-0.52	-0.53	-0.35
Total Liab	0.81	0.81	0.91	0.77	0.46	0.59	0.65	0.34	-0.55		0.16	0.82	0.62	0.25	0.1	0.17	-0.1	0.84	-0.51	-0.6	0.8	0.43	0.78	0.82	0.75	0.79
Intangible Assets	0.6	0.05	0.34	0.63	0.7	0.11	0.35	-0.03	-0.03	0.16		-0.22	0.06	-0.1	0.97	0.95	-0.97	0.37	0.18	0.27	-0.22	-0.22	-0.23	-0.22	-0.3	-0.26
Common Stock	0.47	0.85	0.7	0.41	0.05	0.29	0.56	0.35	-0.54	0.82	-0.22		0.76	0.55	-0.35	-0.13	0.35	0.73	-0.31	-0.83	0.79	0.33	0.99	1.0	0.91	0.76
Property Plant Equipment	0.37	0.7	0.61	0.33	0.32	0.31	0.89	-0.05	-0.33	0.62	0.06	0.76		0.77	-0.14	0.17	0.14	0.81	-0.24	-0.87	0.35	-0.14	0.74	0.78	0.78	0.35
Treasury Stock	0.03	0.52	0.34	0.01	0.01	-0.26	0.59	0.08	-0.13	0.25	-0.1	0.55	0.77		-0.31	-0.05	0.31	0.49	0.27	-0.76	0.13	-0.19	0.57	0.57	0.59	0.15
Long Term Debt	0.56	-0.08	0.26	0.6	0.65	0.17	0.21	-0.04	0.01	0.1	0.97	-0.35	-0.14	-0.31		0.88	-1.0	0.22	0.1	0.44	-0.23	-0.16	-0.36	-0.35	-0.43	-0.28
Good Will	0.57	0.13	0.32	0.6	0.69	0.07	0.38	-0.07	-0.06	0.17	0.95	-0.13	0.17	-0.05	0.88		-0.88	0.43	0.21	0.16	-0.2	-0.24	-0.13	-0.13	-0.2	-0.24
Preferred Stock Total Equity	-0.56	0.08	-0.26	-0.6	-0.65	-0.17	-0.21	0.04	-0.01	-0.1	-0.97	0.35	0.14	0.31	-1.0	-0.88		-0.22	-0.1	-0.44	0.23	0.16	0.36	0.35	0.43	0.28
Other Liab	0.8	0.66	0.74	0.78	0.53	0.42	0.8	0.33	-0.38	0.84	0.37	0.73	0.81	0.49	0.22	0.43	-0.22		-0.27	-0.66	0.62	-0.05	0.68	0.75	0.72	0.58
Net Debt	-0.32	-0.14	-0.33	-0.29	-0.28	-0.96	-0.35	0.17	0.25	-0.51	0.18	-0.31	-0.24	0.27	0.1	0.21	-0.1	-0.27		0.23	-0.46	-0.15	-0.25	-0.32	-0.38	-0.48
Retained Earnings	-0.23	-0.71	-0.53	-0.18	-0.05	-0.2	-0.65	-0.02	0.55	-0.6	0.27	-0.83	-0.87	-0.76	0.44	0.16	-0.44	-0.66	0.23		-0.52	-0.07	-0.82	-0.85	-0.93	-0.52
Cash And Short Term Investments	0.63	0.51	0.54	0.59	0.09	0.41	0.2	0.66	-0.43	0.8	-0.22	0.79	0.35	0.13	-0.23	-0.2	0.23	0.62	-0.46	-0.52		0.34	0.74	0.79	0.77	0.97
Net Receivables	0.12	0.54	0.49	0.08	-0.09	0.08	-0.11	0.12	-0.43	0.43	-0.22	0.33	-0.14	-0.19	-0.16	-0.24	0.16	-0.05	-0.15	-0.07	0.34		0.37	0.29	0.18	0.37
Common Stock Total Equity	0.41	0.88	0.7	0.36	0.02	0.22	0.53	0.32	-0.55	0.78	-0.23	0.99	0.74	0.57	-0.36	-0.13	0.36	0.68	-0.25	-0.82	0.74	0.37		0.99	0.88	0.71
Common Stock Shares Outstanding	0.47	0.84	0.69	0.41	0.06	0.3	0.58	0.34	-0.52	0.82	-0.22	1.0	0.78	0.57	-0.35	-0.13	0.35	0.75	-0.32	-0.85	0.79	0.29	0.99		0.92	0.76
Other Stockholder Equity	0.42	0.71	0.59	0.37	0.13	0.33	0.55	0.27	-0.53	0.75	-0.3	0.91	0.78	0.59	-0.43	-0.2	0.43	0.72	-0.38	-0.93	0.77	0.18	0.88	0.92		0.78
Total Current Assets	0.62	0.51	0.55	0.58	0.19	0.42	0.2	0.64	-0.35	0.79	-0.26	0.76	0.35	0.15	-0.28	-0.24	0.28	0.58	-0.48	-0.52	0.97	0.37	0.71	0.76	0.78

Click cells to compare fundamentals

Enlivex Therapeutics Account Relationship Matchups

Enlivex Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	17.6M	40.4M	95.1M	67.6M	36.8M	30.6M
Other Current Liab	5.5M	3.7M	3.2M	4.0M	4.9M	5.1M
Total Current Liabilities	6.0M	4.4M	4.7M	6.6M	6.1M	3.6M
Total Stockholder Equity	11.3M	35.5M	85.0M	56.8M	30.1M	25.2M
Accounts Payable	316K	463K	878K	1.9M	827K	1.1M
Cash	3.9M	5.7M	11.2M	47.8M	813K	772.4K
Other Assets	(426.0)	0.0	81K	412K	370.8K	253.8K
Short Term Investments	8.1M	30.0M	72.9M	299K	26.5M	13.3M
Other Current Assets	510K	2.4M	2.3M	1.4M	6.4M	3.8M
Total Liab	6.3M	4.9M	10.1M	10.8M	6.7M	5.5M
Common Stock	1.2M	1.6M	2.1M	2.1M	2.1M	2.2M
Property Plant Equipment	1.1M	2.1M	2.5M	14.9M	17.1M	18.0M
Net Debt	(3.8M)	(5.5M)	(10.6M)	(43.0M)	219K	230.0K
Retained Earnings	(25.7M)	(37.5M)	(52.0M)	(83.0M)	(112.1M)	(106.5M)
Cash And Short Term Investments	12.0M	35.7M	84.1M	48.1M	27.3M	23.0M
Net Receivables	2.4M	1.2M	1.1M	647K	229K	217.6K
Common Stock Shares Outstanding	8.6M	13.2M	17.9M	18.4M	18.6M	19.5M
Liabilities And Stockholders Equity	17.6M	40.4M	95.1M	67.6M	36.8M	31.4M
Other Stockholder Equity	37.1M	70.4M	133.8M	136.6M	138.9M	145.9M
Total Current Assets	16.4M	38.1M	86.4M	52.3M	33.8M	28.5M
Property Plant And Equipment Net	1.1M	2.1M	8.2M	14.9M	2.6M	3.0M
Non Current Assets Total	1.1M	2.2M	8.7M	15.3M	3.1M	3.2M
Non Currrent Assets Other	(329K)	8K	482K	105K	179K	188.0K
Property Plant And Equipment Gross	648K	2.1M	10.2M	18.4M	6.6M	4.3M
Accumulated Other Comprehensive Income	(2.3M)	(1.3M)	977K	1.1M	1.3M	1.3M
Non Current Liabilities Total	298K	499K	5.4M	4.2M	686K	651.7K
Net Tangible Assets	11.3M	35.5M	85.0M	56.8M	65.4M	32.8M
Net Invested Capital	11.3M	35.5M	85.0M	56.8M	30.1M	36.3M
Net Working Capital	10.4M	33.7M	81.7M	45.7M	27.7M	33.3M
Capital Stock	1.2M	1.6M	2.1M	2.1M	2.1M	1.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Enlivex Stock Analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC